Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in post-transplant recurrence of C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis
2020-002637-15Phase 2Unknown
- Sponsor
- Apellis Pharmaceuticals
- Start
- Oct 2020
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (2 arms), sponsored by Apellis Pharmaceuticals. Primary endpoint: Reduction in C3c staining on renal biopsy at 12 weeks. Status: unknown.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on 2020-002637-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002637-15.